Clinical efficacy and adverse reactions of tigecycline in treatment of healthcare-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii
10.3969/j.issn.1671-9638.2016.02.006
- VernacularTitle:替加环素治疗泛耐药鲍曼不动杆菌医院获得性肺炎的临床疗效及不良反应
- Author:
Kaige WANG
;
Fen TAN
;
Hong PENG
;
Ping CHEN
- Publication Type:Journal Article
- Keywords:
tigecycline;
extensively drug-resistant Acinetobacter baumannii;
healthcare-associated pneumonia;
cefoperazone-sulbactam
- From:
Chinese Journal of Infection Control
2016;15(2):97-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and adverse reactions of tigecycline in treatment of health-care-associated pneumonia (HAP ) caused by extensively drug-resistant Acinetobacter baumannii (XDRAB ). Methods Clinical data of patients who used tigecycline for the treatment of XDRAB HAP in intensive care units of a hospital from March 2013 to June 2014 were retrospectively analyzed.Results XDRAB isolated from 31 patients with HAP were all sensitive to tigecycline,the resistance rates to carbapenems and sulbactams (including cefopera-zone-sulbactam,SCF)were all 100%,17 cases (54.84%)were mixed infection.Combined use rates of tigecycline and SCF were 85.71 %(12/14)in respiratory intensive care unit(RICU)and 47.06%(8/17)in general intensive care unit(GICU).Of 31 patients,the cure rate,effective rate,bacterial clearance rate,and antimicrobial adverse reac-tion rate were 29.03%,45.16%,61 .29%,and 16.13% respectively,no serious adverse drug reactions occurred. In RICU group and GICU group,the cure rates were 42.86% and 17.65% respectively,effective rates were 71 .43% and 23.53% respectively,and bacterial clearance rates were 78.57 % and 47.06% respectively,difference in effective rate between two groups was significant (P <0.05).Among patients receiving combination of tigecycline and SCF as well as not receiving combined SCF,the cure rates were 35.00% and 18.18% respectively,effective rates were 60.00% and 18.18% respectively,and bacterial clearance rates were 65.00% and 54.55% respectively, difference in effective rate between two groups was significant (P <0.05).Conclusion Tigecycline has a good clini-cal efficacy and little adverse reaction in treating XDRAB HAP;tigecycline combined with SCF is a good choice.
